KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $844.6 million.

  • Regeneron Pharmaceuticals' Net Income towards Common Stockholders fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
  • Regeneron Pharmaceuticals' Net Income towards Common Stockholders amounted to $844.6 million in Q4 2025, which was down 796.56% from $1.5 billion recorded in Q3 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' Net Income towards Common Stockholders peaked at $3.1 billion during Q2 2021, and registered a low of $722.0 million during Q1 2024.
  • In the last 5 years, Regeneron Pharmaceuticals' Net Income towards Common Stockholders had a median value of $1.1 billion in 2021 and averaged $1.3 billion.
  • In the last 5 years, Regeneron Pharmaceuticals' Net Income towards Common Stockholders skyrocketed by 24535.83% in 2021 and then crashed by 7250.31% in 2022.
  • Regeneron Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $2.2 billion in 2021, then plummeted by 46.29% to $1.2 billion in 2022, then dropped by 3.13% to $1.2 billion in 2023, then dropped by 20.86% to $917.7 million in 2024, then dropped by 7.97% to $844.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at $844.6 million for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.